Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 536-539

  Sun, Junping ^a   Zhang, Jia ^a,c   Yan, Wen ^a   Chen, Cai ^a   Wu, Geru ^a   Abbasi, Shahrzad ^a   Pham, Bao ^a   Lee, Steven ^a   Cheng, Jie ^a,b   Memon, Nada B ^b   Xi, Yutao ^a,b  

^a TEXAS HEART INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cardiac progenitor cells; Cardiotoxicity; Doxorubicin; Iloprost

Indexed keywords

CASPASE 3; CASPASE 7; DOXORUBICIN; ILOPROST; ANTINEOPLASTIC ANTIBIOTIC; ANTITHROMBOCYTIC AGENT;

CARDIAC STEM CELL; CELL CULTURE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LETTER; OXIDATIVE STRESS; CELL SURVIVAL; DRUG EFFECTS; HEART MUSCLE CELL; PHYSIOLOGY; STEM CELL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; HUMANS; ILOPROST; MYOCYTES, CARDIAC; PLATELET AGGREGATION INHIBITORS; STEM CELLS;

EID: 84922395379     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.031     Document Type: Article

References (35)

1. Limonta P, Manea M. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treat Rev 2013; 39: 647-63.
2. Dirks-Naylor AJ. The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci 2013; 93: 913-6.
3. van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008: CD003917.
4. Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study. Lancet Oncol 2012; 13: 1234-41.
5. Kobayashi S, Volden P, TimmD, et al. Transcription factor GATA4 inhibits doxorubicininduced autophagy and cardiomyocyte death. J Biol Chem 2010; 285: 793-804.
6. Turakhia S, Venkatakrishnan CD, Dunsmore K, et al. Doxorubicin-induced cardiotoxicity: Direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am J Physiol Heart Circ Physiol 2007; 293: H3111-21.
7. Oliveira MS, Melo MB, Carvalho JL, et al. Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J Cancer Sci Ther 2013; 5: 52-7.
8. Pinarli FA, Turan NN, Pinarli FG, et al. Resveratrol and adipose-derived mesenchymal stem cells are effective in the prevention and treatment of doxorubicin cardiotoxicity in rats. Pediatr Hematol Oncol 2013; 30: 226-38.
9. Momparler RL, Karon M, Siegel SE, et al. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976; 36: 2891-5.
10. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol 1997; 15: 1544-52.
11. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
12. Roodpeyma S, Moussavi F, Kamali Z. Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies. J Pak Med Assoc 2008; 58: 683-7.
13. Alvarez JA, Scully RE, Miller TL, et al. Long-Term effects of treatments for childhood cancers. Curr Opin Pediatr 2007; 19: 23-31.
14. Huang C, Zhang X, Ramil JM, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 2010; 121: 675-83.
15. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010; 121: 276-92.
16. Neilan TG, Jassal DS, Scully MF, et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J 2006; 27: 1251-6.
17. Wang J, Zhang J, Sun J, et al. Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy. Med Hypotheses 2011; 76: 695-6.
18. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A 2007; 104: 14068-73.
19. Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: An in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc 2009; 4: 232-43.
20. Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-71.
21. Nitobe J, Yamaguchi S, Okuyama M, et al. Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res 2003; 57: 119-28.
22. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49: 330-52.
23. Kluza J, Marchetti P, Gallego MA, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004; 23: 7018-30.
24. Kohler AC, Sag CM, Maier LS. Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. J Mol Cell Cardiol 2014.
25. Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 2013; 305: H1417-27.
26. Fornari FA, Randolph JK, Yalowich JC, et al. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45: 649-56.
27. Murakami M, Nakatani Y, Tanioka T, et al. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 2002; 68-69: 383-99.
28. Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002; 300: 367-75.
29. Smith III EF, GallenkamperW, Beckmann R, et al. Early and late administration of a PGI2-Analogue, ZK 36 374 (iloprost): Effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 1984; 18: 163-73.
30. Gryglewski RJ, Swies J. Cardioprotection by molsidomine and iloprost in myocardial ischemia in anaesthetized cats. Agents Actions Suppl 1992; 37: 265-72.
31. Mentz P, Pawelski KE, Giessler C, et al. Significance of the cardioprotective effect of prostanoids and indomethacin. Biomed Biochim Acta 1988; 47: S48-51.
32. Penna C, Mancardi D, Tullio F, et al. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008; 103: 368-77.
33. Jensen BC, Patterson C. Heart factory or fiction?: Cardiac progenitor cells and regeneration. Circulation 2013; 128: 2181-2.
34. Schubert R, Serebryakov VN, Mewes H, et al. Iloprost dilates rat small arteries: Role of K(ATP)-And K(Ca)-channel activation by cAMP-dependent protein kinase. Am J Physiol 1997; 272: H1147-56.
35. Babenko A, Vassort G. Enhancement of the ATP-sensitive K+ current by extracellular ATP in rat ventricular myocytes. Involvement of adenylyl cyclaseinduced subsarcolemmal ATP depletion. Circ Res 1997; 80: 589-600.